<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72222">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945242</url>
  </required_header>
  <id_info>
    <org_study_id>121-012</org_study_id>
    <secondary_id>JapicCTI-132265</secondary_id>
    <nct_id>NCT01945242</nct_id>
  </id_info>
  <brief_title>Alogliptin Tablets Special Drug Use Surveillance &quot;Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones&quot;</brief_title>
  <official_title>Nesina Tablets Special Drug Use Surveillance &quot;Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of long-term combination
      therapy with alogliptin (Nesina) and thiazolidinediones in patients with type 2 diabetes
      mellitus who failed to respond adequately to treatment with thiazolidinediones in addition
      to diet therapy and exercise therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a special drug use surveillance on long-term use of alogliptin with a 1-year
      (12-month) observational period, designed to investigate the safety and efficacy of
      long-term combination therapy with alogliptin and thiazolidinediones in patients with type 2
      diabetes mellitus in a routine clinical setting.

      Participants will be patients with type 2 diabetes mellitus who failed to respond adequately
      to treatment with thiazolidinediones in addition to diet therapy and exercise therapy. The
      planned sample size is 1,000 subjects.

      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Frequency of Adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The frequency of adverse events by type, seriousness, time to onset, etc. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baselin in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline and month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at month 12 relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baselin in Fasting Blood Glucose</measure>
    <time_frame>Baseline and month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the value of fasting blood glucose collected at month 12 relative to baseline.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Type 2 Diabetes Melitus</condition>
  <arm_group>
    <arm_group_label>Alogilptin 25mg, tablets, orally, once daily, up to 12 months</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin tablets</description>
    <arm_group_label>Alogilptin 25mg, tablets, orally, once daily, up to 12 months</arm_group_label>
    <other_name>Nesina; SYR-322</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes mellitus who have been examined at a medical institution
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who did not adequately respond to the following treatment â€¢ Treatment with
             thiazolidinediones in addition to diet therapy and exercise therapy

        Exclusion Criteria:

          -  Patients contraindicated for Nesina

               1. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes
                  mellitus (these patients require prompt adjustment of hyperglycemia by fluid
                  infusion and insulin, and hence use of Nesina is not appropriate.)

               2. Patients with severe infection, pre- or post-operative patients, or patients
                  with serious traumatic injury (blood glucose control by insulin injection is
                  desirable for these patients, and hence use of Nesina is not appropriate.)

               3. Patients with a history of hypersensitivity to any ingredient of Nesina
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>2,4-thiazolidinedione</mesh_term>
    <mesh_term>Alogliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
